- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01638949
Multi-modal Neuroimaging in Alzheimer's Disease (IMAP+)
Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging
Study Overview
Status
Conditions
Detailed Description
The three main objectives of this project are:
- To Identify, compare and combine the predictive markers of AD,
- To better understand the pathophysiologic mechanisms of AD,
- To study the ability of different neuroimaging techniques to monitor AD's evolution.
For these purposes, detailed neuropsychological evaluations, biological measures and brain structural & functional imaging measures are associated for a fully-comprehensive description of the different manifestations of AD through disease progression and toward identifying early markers.
Subjects are evaluated using neuropsychological tests of episodic memory (encoding vs. retrieval), executive functions (inhibition, flexibility, and updating processes), self-judgment, theory of mind, mental imagery and verbal fluency. A FDG-PET measure of resting state glucose consumption, an AV45-PET measure of amyloid deposition as well as anatomical, resting-state and activation fMRI scans are performed for each volonteer. In addition, blood and cerebro-spinal fluid samples will be performed to determine different biomarkers (Aβ1-40, Aβ1-42 and tPA as circulating blood proteins and Aβ40, Aβ42, tau and its phosphorylated form in CSF). The investigators also study the polymorphism of Apolipoprotein E as a genetic risk factor of AD.
One hundred and twenty healthy controls (40 young, 40 middle age and 40 elderly), 40 Mild Cognitive Impairment patients (MCI; i.e. isolated memory impairment and increased risk of developing AD) and 30 AD patients will be selected. Participants with increased risk of developing AD and without objective evidence will be also studied: 50 asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission (NORMA) and 40 Subjective Cognitive Impairment patients (SCI).
Clinical follow-up of patients will be completed during 36 months (18 months for AD patients), as a neuropsychological evaluation every 6 months. Comparable neuropsychological and imaging exams will be proposed once again after 18 months for all participants as well as after 36 months for elderly controls, NORMA and SCI & MCI patients.
To study and compare the effectiveness of different in vivo markers (to predict cognitive decline in populations at risk of developing AD), each data set (i.e. modality) will be first analyzed independently from one another (intra-modality analyses), including inter-group comparisons, correlations and connectivity analyses, as well as longitudinal assessment of cognitive, biological and brain changes. Baseline data will also be analyzed in function of patient's clinical evolution to assess their predictive value. Comparisons and correlations between the different patterns of alterations will then be performed through inter-modality analyses. More specifically, the investigators will address the questions of the relationships between cognitive and cerebral alterations and structural / functional brain changes over our different patient samples, neuroimaging data sets, and through disease evolution.
This project is expected to identify specific and early markers of the MA and also to compare the diagnostic efficiency of different measures. It should contribute to better understand brain and cognitive alterations in AD. Finally, the investigators will be able to appreciate the dynamic properties of these alterations in the evolution of the disease through the longitudinal study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julien Chavant
- Phone Number: +33231065495
- Email: memoire-recherche.caen@inserm.fr
Study Locations
-
-
-
Caen, France, 14033
- University Hospital Côte de Nacre
-
Caen, France, 14000
- Inserm - EPHE - University of Caen U1077
-
Lille, France, 59037
- University Hospital Roger Salengro
-
Rennes, France, 35033
- University Hospital Pontchaillou
-
Rouen, France, 76031
- University Hospital Rouen
-
Tours, France, 37044
- university hospital Tours
-
-
Calvados
-
Caen, Calvados, France, 14000
- GIP Cyceron
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria :
- Education level > 7 years
- Native language: French
Medical, neurological, neuropsychological and neuroradiological depth in accordance with the criteria for inclusion and exclusion-specific population, that is to say:
- Healthy young volunteers: between 18 and 40 years old; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
- Healthy Middle-aged volunteers: between 40 and 60 years old; without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
- Healthy Elderly volunteers: over 60 years old, living at home, without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
- SCI patients: over 60 years old ; memory complaints; memory complaint ; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
- MCI patients: presenting the current criteria for amnestic MCI including: i) memory complaint, ii) deficits of the episodic memory (lower performance of at least 1.65 SD from the norm for age and cultural level for one or more scores of episodic memory and iii) normal performances compared to the age and the educational level of all other cognitive functions as memory, including tests to assess cognitive abilities.
- Alzheimer's patients: presenting the standard criteria of NINCDS-ADRDA probable Alzheimer's disease, including abnormal global cognitive function and deficits in at least two cognitive domains identified by the diagnostic battery and a mild to moderate Alzheimer's disease (MMSE ≥ 15).
Exclusion Criteria :
- The sudden onset of cognitive impairments (as opposed to their slow and gradual installation in Alzheimer's disease)
- A chronic neurological, psychiatric, endocrine, hepatic or infectious complaint
- A history of major disease (an uncontrolled diabetes, a lung, heart, metabolic, hematologic, endocrine disease or a severe cancer)
- A medication that may interfere with memory or metabolic measures
- A alcohol or drugs abuse
- The cons-indications to MRI (claustrophobia, metallic object in the body)
- A predominantly left-hand (score below 50% in Edinburgh Inventory)
- Protected adults, and persons not affiliated with a social security system will not participate in this study
- The inclusion of a participant in another biomedical research protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Young controls
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Middle age controls
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Elderly controls
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Asymptomatic subjects
Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Subjectif Cognitive Impariment patients
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Mild Cognitive Impairment patients
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Alzheimer Disease patients
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
Experimental: Non degenerative amnsesic syndrome
|
Neuropsycological tests including clinical and original tests to compare differences between each populations.
ELISA tests from blood samples to compare differences between each populations.
Evaluation of apolipoprotein E polymorphism as a risk factor.
Structural and functional MRI FDG-PET to compare differences between each populations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of volume change of whole brain, hippocampus and other structural MRI measures
Time Frame: 3 years
|
3 years
|
Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes
Time Frame: 3 years
|
3 years
|
Rates of change on each specified biochemical biomarker
Time Frame: 3 years
|
3 years
|
Rates of change of glucose metabolism (FDG-PET)
Time Frame: 3 years
|
3 years
|
Extent of amyloid deposition as measured by 18F-AV45
Time Frame: 3 years
|
3 years
|
Group differences for each imaging and biomarker measurement
Time Frame: 3 years
|
3 years
|
APOE genotype
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vincent de La Sayette, MD, University Hospital, Caen
Publications and helpful links
General Publications
- Kuhn E, Moulinet I, Perrotin A, La Joie R, Landeau B, Tomadesso C, Bejanin A, Sherif S, De La Sayette V, Desgranges B, Vivien D, Poisnel G, Chetelat G. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimers Res Ther. 2019 Jul 8;11(1):61. doi: 10.1186/s13195-019-0514-z.
- Gonneaud J, Arenaza-Urquijo EM, Fouquet M, Perrotin A, Fradin S, de La Sayette V, Eustache F, Chetelat G. Relative effect of APOE epsilon4 on neuroimaging biomarker changes across the lifespan. Neurology. 2016 Oct 18;87(16):1696-1703. doi: 10.1212/WNL.0000000000003234. Epub 2016 Sep 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-A01493-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Memory assessment
-
University Hospital, CaenInstitut National de la Santé Et de la Recherche Médicale, FranceUnknown
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
University Hospital, CaenInstitut National de la Santé Et de la Recherche Médicale, France; National...Unknown
-
University Hospital, GhentCompletedAphasia, Acquired | Short-Term Memory ImpairmentBelgium
-
Sorlandet Hospital HFUnknownMild Cognitive ImpairmentNorway
-
Henry Ford Health SystemNot yet recruiting
-
Sage BionetworksRobert Wood Johnson FoundationUnknownBrain Diseases | Central Nervous System Diseases | Parkinson Disease | Parkinsonian Disorders | Basal Ganglia Diseases | Movement Disorders | Neurodegenerative DiseasesUnited States
-
Johns Hopkins UniversityTerminatedSubstance-Related DisordersUnited States
-
John Wesson Ashford JrUS Department of Veterans AffairsActive, not recruiting
-
Centre for Addiction and Mental HealthCompleted